LCCC1227; Prospective Evaluation of the Effect of Curcumin on Dose-limiting Toxicity and Pharmacokinetics of Irinotecan in Colorectal Cancer Patients
Investigating the Effects of Curcumin on Irinotecan Metabolism
Brief description of study.
The purpose of this study is to better understand the interaction between curcumin and irinotecan by measuring levels of irinotecan in the blood (ie. measure irinotecan PK) when a patient also takes curcumin.
Detailed description of study
This is a single-center, two-part, open label prospective study to define the maximum tolerated dose (MTD) of curcumin plus irinotecan and the pharmacokinetic effects of curcumin on irinotecan metabolism in patients with advanced colorectal cancer.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Colorectal Cancer
-
Age: 21 years - 100 years
-
Gender: All
This study investigates how curcumin affects the levels of irinotecan in the blood. Irinotecan is a medication used in cancer treatment, and pharmacokinetics (PK) refers to how the drug moves through the body. The study aims to understand this interaction in patients with advanced colorectal cancer.
Participants will receive both curcumin and irinotecan to determine the maximum tolerated dose of curcumin when combined with irinotecan. The study will measure how curcumin influences the breakdown and absorption of irinotecan in the body.
- Who can participate: Adults aged 18 and older with advanced colorectal cancer are eligible to participate. Key eligibility factors include previous treatment with irinotecan and no known allergies to curcumin.
- Study details: Participants will take curcumin along with irinotecan. The study will measure blood levels to understand the interaction between these substances.
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or